BRCA1 and breast carcinoma: For instance, although 23andMe®’s breast cancer reports explicitly state that the three BRCA1/2 pathogenic variants being tested do not include other BRCA1/2 pathogenic variants relevant for breast cancer risk [4], it is unclear whether patient comprehension of incomplete results in this setting will translate to PGS-based tests.